Department of Pediatrics, New York-Presbyterian Morgan Stanley Children's Hospital, Columbia University, New York, NY, USA.
Biol Blood Marrow Transplant. 2011 Oct;17(10):1472-80. doi: 10.1016/j.bbmt.2011.02.006. Epub 2011 Feb 18.
Pediatric allogeneic stem cell transplant (AlloSCT) patients are at substantial risk of developing kidney injury (KI), and KI contributes to transplant-related morbidity and mortality. We compared the estimated creatinine clearance (eCrCl) at 1, 3, 6, 9, and 12 months post-AlloSCT in 170 patients following reduced toxicity conditioning (RTC) versus myeloablative conditioning (MAC) to baseline. eCrCl was calculated using the Schwartz equation. Patients with ≥ 50% drop in eCrCl from the baseline were considered to have KI. Patients received tacrolimus and mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis. The logistic regression model was used for assessing risk factors for KI. Seventy-six patients (median age = 10.6 years) received RTC AlloSCT; 94 patients (median age = 8.5 years) received MAC AlloSCT. The incidence of KI at 1 month post-AlloSCT was significantly higher in MAC versus RTC AlloSCT (43/94 [45.7%] versus 13/76 [17.1%] P < .0001). There was no statistical difference in KI at 3, 6, 9, and 12 months post-AlloSCT between the 2 conditioning groups. On multivariate analysis, only MAC was a significant risk factor for KI (odds radio [OR] 3.44, 95% confidence interval [CI] 1.59-7.42, P = .002). In multivariate analysis for risk factors affecting overall survival (OS), the following were statistically significant: MAC versus RTC (hazard ratio [HR] 2.66, P = .0008), average versus poor-risk disease status (HR 2.09, P = .004), matched sibling donor (MSD) and matched unrelated donor (MUD) versus umbilical cord blood (UCB) (HR 2.31, P = .013), no KI versus KI (HR 2.00, P = .005). In children, MAC is associated with significant risk of KI in the first month after transplant, and KI in the first month post-AlloSCT is associated with a significantly decreased OS.
儿科异基因造血干细胞移植(AlloSCT)患者发生肾脏损伤(KI)的风险较大,且 KI 会导致移植相关发病率和死亡率升高。我们比较了 170 例接受减毒预处理(RTC)与骨髓清除性预处理(MAC)的 AlloSCT 患者在移植后 1、3、6、9 和 12 个月的估计肌酐清除率(eCrCl)与基线相比的变化。采用 Schwartz 方程计算 eCrCl。将 eCrCl 从基线下降≥50%的患者视为发生 KI。患者接受他克莫司和吗替麦考酚酯(MMF)预防移植物抗宿主病(GVHD)。采用逻辑回归模型评估 KI 的危险因素。76 例患者(中位年龄=10.6 岁)接受 RTC AlloSCT;94 例患者(中位年龄=8.5 岁)接受 MAC AlloSCT。MAC 组患者移植后 1 个月的 KI 发生率显著高于 RTC 组(43/94[45.7%]比 13/76[17.1%],P<0.0001)。两组患者在移植后 3、6、9 和 12 个月的 KI 发生率无统计学差异。多因素分析显示,仅 MAC 是 KI 的显著危险因素(比值比[OR]3.44,95%置信区间[CI]1.59-7.42,P=0.002)。多因素分析影响总生存(OS)的危险因素时,以下因素有统计学意义:MAC 比 RTC(风险比[HR]2.66,P=0.0008)、一般风险与不良风险疾病状态(HR 2.09,P=0.004)、同胞供者(MSD)和无关供者(MUD)与脐带血(UCB)(HR 2.31,P=0.013)、无 KI 与 KI(HR 2.00,P=0.005)。在儿童中,MAC 与移植后第一个月 KI 的发生风险显著相关,且 AlloSCT 后第一个月的 KI 与显著降低的 OS 相关。